- mAbxience and Teva enter into a strategic global partnership for in-licensing of an oncology biosimilar candidate
- Agreement signals a major step in mAbxience’s global expansion strategy and advances a key element of Teva’s Pivot to Growth strategy to expand its biosimilar pipeline through business development
- mAbxience-Teva partnership reflects the companies’ shared commitment to expand access to critical healthcare solutions to more patients who need them
MADRID, SPAIN and TEL AVIV, ISRAEL, April 4th, 2024 — mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, and Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced they have entered a strategic licensing agreement for a biosimilar candidate currently in development for the treatment of multiple oncology indications. Biosimilars show promising potential in providing more cost-effective alternatives to existing oncology therapies, thereby addressing a critical need in global oncology care.
The licensing agreement covers multiple global markets, including in Europe and the United States, signaling a major step in mAbxience’s global expansion strategy, and supports a key element of Teva’s Pivot to Growth strategy, announced in 2023, to expand its biosimilar pipeline through business development and strategic partnerships.
Under the terms of the licensing agreement, mAbxience will leverage its expertise in biosimilar development and its state-of-the-art, current Good Manufacturing Practice (cGMP)-approved facilities in Spain and Argentina, to develop and produce the biosimilar product. Teva will lead the regulatory processes and commercialization in the designated regions, to ensure access to a broader patient population.
“Partnering with Teva not only reinforces mAbxience’s position as a global biosimilar company but also aligns with our mission to deliver high-quality, affordable healthcare solutions across continents,” says Jurgen Van Broeck, Global Commercial Director of mAbxience. “This agreement will assist healthcare systems in reducing costs, ensuring the provision of these vital cancer treatments to all patients who require them.”
“Teva is pleased to form this strategic alliance with mAbxience, who share our commitment to accelerate the delivery of impactful medicines to patients worldwide,” says Angus Grant, PhD, Executive Vice President of Business Development at Teva. “This collaboration reflects Teva’s ideal strategic partnership model to optimize development costs, mitigate risk and leverage our extensive commercial capabilities.”
